Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000582722 | SCV000687823 | likely benign | Hereditary cancer-predisposing syndrome | 2016-12-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002061694 | SCV002335486 | likely benign | Ataxia-telangiectasia syndrome | 2023-12-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002506391 | SCV002803560 | likely benign | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001354371 | SCV001548973 | uncertain significance | Malignant tumor of breast | no assertion criteria provided | clinical testing | The ATM c.8268+13A>T variant was not identified in the literature nor was it identified in the dbSNP, Clinvitae, COGR, or LOVD 3.0 databases. The variant was identified in ClinVar (classified as likely benign by Color Genomics). The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The variant occurs outside of the splicing consensus sequence and 2 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |